The Pharmaceutical Journal
Vol 274 No 7346 p483
23 April 2005

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Cannabis MS medicine approved

Canada has become the first country to approve a new cannabis medicine as adjunctive treatment for the symptomatic relief of neuropathic pain in adults with multiple sclerosis.

Sativex (Cannabis sativa L. extract) is not yet available in the UK but is being reviewed by the regulatory authorities for the treatment of spasticity in MS. This review is due to be completed this summer.